News VYNE Therapeutics Inc.

Equities

VYNE

US92941V3087

Market Closed - Nasdaq Other stock markets 04:00:00 2023-11-27 pm EST			5-day change	1st Jan Change
3.970 ^USD	-1.00%		+0.51%	+47.04%

Nov. 13	Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q3 Revenue $114,000	MT
Nov. 13	VYNE Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Summary

Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q3 Revenue $114,000	Nov. 13	MT
VYNE Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update	Nov. 13	AQ
Transcript : VYNE Therapeutics Inc. - Special Call	Nov. 09	CI
VYNE Therapeutics to Host Virtual R&D Day Event on November 9, 2023	Nov. 07	AQ
VYNE Therapeutics Announces Closing of Previously Announced Private Placement of $88.2 Million	Nov. 01	AQ
VYNE Therapeutics Inc. announced that it has received $88.151509 million in funding from Acorn Bioventures, Parkman Healthcare Partners LLC, Soleus Capital, Surveyor Capital Management, Palo Alto Investors LP and other investors	Oct. 31	CI
Wall Street Set to Open Higher Monday as Investors Parse Earnings, Await Fed Meeting	Oct. 30	MT
Top Premarket Gainers	Oct. 30	MT
VYNE Therapeutics Reports Positive Results from Preclinical Models for Oral BD2-Selective BET Inhibitor VYN202	Oct. 30	AQ
Investors Look Ahead to FOMC Meeting, Earnings Reports as US Futures Trend Higher Monday	Oct. 30	MT
VYNE Therapeutics Announces Private Placement of $88 Million	Oct. 30	AQ
VYNE Therapeutics Announces Positive Data from Phase 1b Trial for Novel BET Inhibitor VYN201 in Patients with Nonsegmental Vitiligo	Oct. 30	AQ
VYNE Therapeutics Inc. Announces Positive Data from Phase 1b Trial for Novel Bet Inhibitor VYN201 in Patients with Nonsegmental Vitiligo	Oct. 30	CI
VYNE Therapeutics Inc. announced that it expects to receive $88.151509 million in funding	Oct. 26	CI
VYNE Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference	Sep. 06	AQ
VYNE Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update	Aug. 14	AQ
Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q2 Revenue $135,000	Aug. 14	MT
VYNE Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	Aug. 14	CI
VYNE Therapeutics to Attend BIO International Convention	May. 18	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies

News VYNE Therapeutics Inc.

Equities

VYNE

US92941V3087

Summary

Filters